Welcome to our dedicated page for Mediwound SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MediWound Ltd. (MDWD) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. MediWound files reports on Form 6-K to furnish press releases, financial statements, and transaction details, and uses shelf registration statements on Form F-3 and employee share plans on Form S-8 for capital markets activities. These documents provide structured insight into the company’s biotechnology business focused on enzymatic, non-surgical therapies for tissue repair.
In its Form 6-K filings, MediWound furnishes quarterly and interim financial results, including condensed consolidated statements of financial position and profit or loss, along with management press releases discussing revenue, operating loss, cash balances, and non-IFRS measures such as Adjusted EBITDA. Other 6-Ks describe registered direct offerings of ordinary shares under an effective Form F-3 shelf registration statement, including purchase agreements, use of proceeds for EscharEx® pre-commercial activities and manufacturing expansion, and related legal opinions.
Filings also reference government-supported programs and contracts that are important to MediWound’s burn and chronic wound portfolio. BARDA- and U.S. Department of Defense-funded projects for NexoBrid®, including clinical development, regulatory submissions, emergency procurement, and formulation work, are discussed in the company’s press releases that are incorporated by reference into SEC reports. Insider share purchases by senior leadership are reported on Form 6-K, providing transparency into management’s trading activity.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain key points from lengthy filings, highlight changes in financial condition, and surface important details about offerings, grants, and clinical or manufacturing milestones. Users can quickly locate quarterly updates, registration statements, and reports that reference NexoBrid and EscharEx, and review how MediWound describes its risks, funding, and strategic priorities over time.
MediWound Ltd. has called an extraordinary general meeting for February 19, 2026 to ask shareholders to approve an increase of 300,000 ordinary shares reserved for issuance under its 2024 Share Incentive Plan. The record date for voting is the close of business on January 16, 2026, when 12,835,186 ordinary shares were issued and outstanding, with each share entitled to one vote.
The Board and compensation committee say the additional shares are needed to continue granting equity awards to employees, officers, directors and other service providers, since only about 132,996 unallocated shares remain available under the plan. If approved, the total equity incentive pool across the 2014 and 2024 plans would cover 1,724,819 shares on a fully diluted base of 16,826,464 shares, representing 10.25% potential dilution. The Board unanimously recommends voting “FOR” the proposal and plans to register the new 300,000-share pool on an additional Form S-8 after approval.
MediWound Ltd. filed a Form 6-K presenting a corporate update and multi‑year financial outlook ahead of the J.P. Morgan Healthcare Conference. The company reports approximately $17 million in 2025 revenue and now guides for $24–26 million in 2026, $32–35 million in 2027, and $50–55 million in 2028, supported by a $54 million cash position. Management notes that U.S. government shutdown–related delays affected fourth‑quarter revenue recognition but characterizes the impact as timing‑related.
The update highlights clinical and operational milestones. An interim assessment and enrollment completion for the Phase III EscharEx® VALUE trial in venous leg ulcers are expected by year‑end 2026, with planned expansion into diabetic foot and pressure ulcers during 2026. MediWound also reports that its expanded NexoBrid® manufacturing facility is fully operational, with regulatory approvals targeted for 2026. The revenue expectations and cash figures are described as preliminary, unaudited, and subject to change after year‑end 2025 audit procedures.
MediWound Ltd. submitted a Form 6-K to furnish a press release titled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update.” The filing notes that the full press release is attached as Exhibit 99.1 and contains the detailed financial and corporate information for the third quarter of 2025.
The company also states that the information in this Form 6-K, including Exhibit 99.1 but excluding quotes from senior management, is incorporated by reference into multiple existing registration statements on Form S-8 and Form F-3. This allows the attached information to be used in connection with those previously filed securities registration documents.
MediWound Ltd. (MDWD): Schedule 13D/A Amendment No. 6 filed by Access Industries affiliates, Clal entities, and Len Blavatnik updates ownership details. The group reports beneficial ownership of 1,481,521 Ordinary Shares, representing 11.56% of the class, based on 12,821,433 shares outstanding as of September 30, 2025.
Most reporting persons list shared voting and dispositive power over 1,481,521 shares. Clal Life Sciences L.P. directly owns 1,172,710 shares (9.15%) with sole voting and dispositive power. Clal Biotechnology Industries Ltd. directly owns 308,811 shares and may be deemed to share voting and investment power over the 1,172,710 shares held by Clal Life Sciences L.P. The amendment revises Items 5(a) and 5(b); the date of event is September 30, 2025.
MediWound Ltd. submitted a Form 6-K reporting corporate disclosures and attachments. The filing lists the company's principal executive office address in Yavne, Israel, and indicates the company files annual reports on Form 20-F. The exhibits include a legal opinion from Meitar | Law Offices and Exhibit 10.1, a Form of Securities Purchase Agreement dated September 29, 2025, executed by the company and the purchasers listed on the signature pages. The filing also includes the consent of Meitar as Exhibit 23.1. No financial tables or earnings data are provided in the disclosed text.
MediWound Ltd. is offering 1,734,105 ordinary shares (MDWD) in a registered placement to institutional and accredited investors. The prospectus supplement states the company’s shares trade on Nasdaq and the last reported price was $17.89 on September 26, 2025, while the offering price described is $17.30 per share. Net proceeds are estimated at approximately $27.4 million after fees, which MediWound intends to use primarily to support the pre-commercial activities for EscharEx, expand large-scale manufacturing capacity and for general corporate purposes. The filing discloses immediate dilution to new investors: net tangible book value was $1.84 per share as of June 30, 2025, rising to an as-adjusted $3.76 per share after the offering, producing approximately $13.54 per-share dilution for purchasers. The placement agent is H.C. Wainwright & Co., with a cash fee of 7.0% of gross proceeds (subject to reductions for certain investors) and additional expense allowances. The supplement also summarizes pipeline and corporate facts: NexoBrid is approved in more than 40 countries, EscharEx is in a global Phase III VALUE trial enrolling 216 VLU patients across ~40 U.S. and European sites with an interim sample-size assessment planned mid-2026, and MW005 has positive Phase I/II data. The document highlights fundraising, dilution, tax and legal disclosures and incorporates by reference the company’s Form 20-F and other filings.
MediWound Ltd. announced a $30 million registered direct offering of ordinary shares. The disclosure in this Form 6-K references a press release titled "MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares." The filing provides the existence and size of the offering but does not include pricing, number of shares, underwriters, or stated use of proceeds within the text provided. Additional offering particulars and material terms are not present in the supplied content.
HOLD Alapkezelo Zrt. filed a Schedule 13G reporting beneficial ownership of 703,429 common shares of MediWound Ltd., representing approximately 6.52% of the outstanding common stock based on 10,793,057 shares outstanding as of December 31, 2024. The filer is a Hungarian investment fund management company (not SEC-registered) with sole voting and dispositive power over the reported shares. The filing states the shares were not acquired to influence control of the issuer. MediWound's principal executive offices are listed in Yavne, Israel.
MediWound Ltd. reports that its Chairman, Nachum (Homi) Shamir, and Chief Executive Officer, Ofer Gonen, each individually purchased the company’s ordinary shares in open market transactions on August 18, 2025. These insider purchases totaled 11,200 ordinary shares at an average price of $17.74 per share.
The company states that all trades complied with its insider trading policy. This report is also being used to incorporate its contents by reference into multiple existing MediWound registration statements on Forms S-8 and F-3 filed with the SEC.
MediWound Ltd. filed a Form 6-K reporting submission of its quarterly materials for the period ended June 30, 2025. The report attaches a press release and the companys financial statements for the quarter and six months ended June 30, 2025, formatted in XBRL. The filing lists the specific XBRL sub-exhibits and states these materials are incorporated by reference into multiple S-8 and F-3 registration statements. The document does not include numerical results or management commentary within the main text of the 6-K itself.